Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo

Nature Biotechnology

Volumn 33, Issue 1, 2015, Pages 73-80

  Zuris, John A ^a,b   Thompson, David B ^a,b   Shu, Yilai ^c,d,e,f   Guilinger, John P ^a,b   Bessen, Jeffrey L ^a,b   Hu, Johnny H ^a,b   Maeder, Morgan L ^c,g   Joung, J Keith ^c,g   Chen, Zheng Yi ^c,d   Liu, David R ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^e FUDAN UNIVERSITY   (China)

^f Key Laboratory of Health Ministry for Hearing Medicine   (China)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; GENES; NUCLEIC ACIDS;

CULTURED HUMAN CELL; DNA TRANSFECTION; ENDOSOMAL ESCAPES; GENOME MODIFICATION; INTRACELLULAR DELIVERY; PROTEIN THERAPEUTICS; TRANSCRIPTION ACTIVATORS; TRANSFECTION REAGENTS;

PROTEINS;

CAS9:SGRNA; CRE RECOMBINASE; LIPOSOME; RNA; TRANSACTIVATOR PROTEIN; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR VP64; UNCLASSIFIED DRUG; CATION; LIPID; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; DNA TRANSFECTION; DRUG DELIVERY SYSTEM; GENOME; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INNER EAR; NONHUMAN; PRIORITY JOURNAL; RNA EDITING; GENETIC TRANSFECTION;

CATIONS; IN VITRO TECHNIQUES; LIPIDS; PROTEINS; TRANS-ACTIVATORS; TRANSFECTION;

EID: 84961288301     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3081     Document Type: Article

References (46)

1. Putney, S.D. & Burke, P.A. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol. 16, 153-157 (1998).
2. Mullen, L. et al. Latent cytokines for targeted therapy of inflammatory disorders. Expert Opin. Drug Deliv. 11, 101-110 (2014).
3. Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709-717 (2005).
4. Leader, B., Baca, Q.J. & Golan, D.E. Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7, 21-39 (2008).
5. Hartung, S.D. et al. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human a-L-iduronidase gene. Mol. Ther. 9, 866-875 (2004).
6. Wang, J. et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat. Biotechnol. 26, 901-908 (2008).
7. Urnov, F.D., Rebar, E.J., Holmes, M.C., Zhang, H.S. & Gregory, P.D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 11, 636-646 (2010).
8. Sander, J.D. & Joung, J.K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 32, 347-355 (2014).
9. Midoux, P., Pichon, C., Yaouanc, J.-J. & Jaffrès, P.-A. Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br. J. Pharmacol. 157, 166-178 (2009).
10. Bodles-Brakhop, A.M., Heller, R. & Draghia-Akli, R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol. Ther. 17, 585-592 (2009).
11. Kay, M.A., Glorioso, J.C. & Naldini, L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7, 33-40 (2001).
12. Zangi, L. et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat. Biotechnol. 31, 898-907 (2013).
13. Wadia, J.S., Stan, R.V. & Dowdy, S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10, 310-315 (2004).
14. Daniels, D.S. & Schepartz, A. Intrinsically cell-permeable miniature proteins based on a minimal cationic PPII motif. J. Am. Chem. Soc. 129, 14578-14579 (2007).
15. Cronican, J.J. et al. Potent delivery of functional proteins into mammalian cells in vitro and in vivo using a supercharged protein. ACS Chem. Biol. 5, 747-752 (2010).
16. Thompson, D.B., Cronican, J.J. & Liu, D.R. Engineering and identifying supercharged proteins for macromolecule delivery into mammalian cells. Methods Enzymol. 503, 293-319 (2012).
17. Thompson, D.B., Villaseñor, R., Dorr, B.M., Zerial, M. & Liu, D.R. Cellular uptake mechanisms and endosomal trafficking of supercharged proteins. Chem. Biol. 19, 831-843 (2012).
18. Allen, T.M. & Cullis, P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65, 36-48 (2013).
19. Shete, H.K., Prabhu, R.H. & Patravale, V.B. Endosomal escape: a bottleneck in intracellular delivery. J. Nanosci. Nanotechnol. 14, 460-474 (2014).
20. Aguilera, T.A., Olson, E.S., Timmers, M.M., Jiang, T. & Tsien, R.Y. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr. Biol. (Camb.) 1, 371-381 (2009).
21. Coelho, T. et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369, 819-829 (2013).
22. Judge, A.D., Bola, G., Lee, A.C.H. & MacLachlan, I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13, 494-505 (2006).
23. Basha, G. et al. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol. Ther. 19, 2186-2200 (2011).
24. Zelphati, O. et al. Intracellular delivery of proteins with a new lipid-mediated delivery system. J. Biol. Chem. 276, 35103-35110 (2001).
25. Adrian, J.E. et al. Targeted SAINT-O-Somes for improved intracellular delivery of siRNA and cytotoxic drugs into endothelial cells. J. Control. Release 144, 341-349 (2010).
26. Morris, M.C., Depollier, J., Mery, J., Heitz, F. & Divita, G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol. 19, 1173-1176 (2001).
27. Colletier, J.-P., Chaize, B., Winterhalter, M. & Fournier, D. Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer. BMC Biotechnol. 2, 9 (2002).
28. Lawrence, M.S., Phillips, K.J. & Liu, D.R. Supercharging proteins can impart unusual resilience. J. Am. Chem. Soc. 129, 10110-10112 (2007).
29. Liu, J., Gaj, T., Patterson, J.T., Sirk, S.J. & Barbas, C.F. III. Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering. PLoS ONE 9, e85755 (2014).
30. Tessarollo, L., Vogel, K.S., Palko, M.E., Reid, S.W. & Parada, L.F. Targeted mutation in the neurotrophin-3 gene results in loss of muscle sensory neurons. Proc. Natl. Acad. Sci. USA 91, 11844-11848 (1994).
31. Maeder, M.L. et al. Robust, synergistic regulation of human gene expression using TALE activators. Nat. Methods 10, 243-245 (2013).
32. Fu, Y., Sander, J.D., Reyon, D., Cascio, V.M. & Joung, J.K. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat. Biotechnol. 32, 279-284 (2014).
33. McNaughton, B.R., Cronican, J.J., Thompson, D.B. & Liu, D.R. Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins. Proc. Natl. Acad. Sci. USA 106, 6111-6116 (2009).
34. Ramakrishna, S. et al. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. 24, 1020-1027 (2014).
35. Qi, L.S. et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173-1183 (2013).
36. Guschin, D.Y. et al. A rapid and general assay for monitoring endogenous gene modification. Methods Mol. Biol. 649, 247-256 (2010).
37. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
38. Ran, F.A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380-1389 (2013).
39. Maeder, M.L. et al. CRISPR RNA-guided activation of endogenous human genes. Nat. Methods 10, 977-979 (2013).
40. Guilinger, J.P., Thompson, D.B. & Liu, D.R. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat. Biotechnol. 32, 577-582 (2014).
41. Pattanayak, V. et al. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat. Biotechnol. 31, 839-843 (2013).
42. Gilleron, J. et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31, 638-646 (2013).
43. Lumpkin, E.A. et al. Math1-driven GFP expression in the developing nervous system of transgenic mice. Gene Expr. Patterns 3, 389-395 (2003).
44. Sojung Kim, D.K. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 10.1101/gr.171322.113 (2014).
45. Yin, H. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551-553 (2014).
46. Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910-918 (2013).